Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 12/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124258 | 0.86 | GRM2 (0.50) | PIK3CGGRM2MAPK1DPP4DPP7 | |
| SCHEMBL2122782 | 0.85 | LMNA (0.48) | PIK3CGGRM2MAPK1 | |
| SCHEMBL2124468 | 0.75 | GRM2 (0.66) | PIK3CGGRM2DPP4DPP7IDH1 | |
| SCHEMBL3085170 | 0.74 | L3MBTL1 (0.36) | PIK3CGMAPK1PIK3CDPIK3R1PIK3CA | |
| SCHEMBL2125662 | 0.74 | L3MBTL1 (0.36) | PIK3CGMAPK1PIK3CDPIK3R1PIK3CA | |
| SCHEMBL8270164 | 0.72 | PIK3CG (0.50) | PIK3CGMAPK1PIK3CDPIK3R1 | |
| SCHEMBL2022806 | 0.72 | PIK3CG (0.50) | PIK3CGMAPK1PIK3CDPIK3R1 | |
| SCHEMBL2027746 | 0.72 | PIK3CG (0.50) | PIK3CGMAPK1PIK3CDPIK3R1 | |
| SCHEMBL2123223 | 0.69 | GRM2 (0.58) | GRM2MAPK1 | |
| SCHEMBL2025196 | 0.69 | PIK3CG (0.40) | PIK3CGMAPK1PIK3CDPIK3R1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2442649-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | claimed |
| WO-2010148074-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | Astrazeneca Pharmaceuticals (US) | 2010-12-23 | — | — | WO | claimed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | claimed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | claimed |
| EP-2167501-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | claimed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | claimed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-2442649-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010148074-A1 | THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE | Astrazeneca Pharmaceuticals (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | GRM1, GRM3, GRM2 | PIK3CG 2647/4885GRM2 3/4885MAPK1 1931/4885 |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | GRM1, GRIN1, GRM3 | PIK3CG 2449/4885GRM2 5/4885MAPK1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.